Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 9, 2004

View Archived Issues

S-21403 reported to reduce the effects of postprandial hyperglycemia in type 2 diabetes

Four series of PPAR modulators reported by Lilly

Novel CGRP antagonists for migraine therapy presented by Boehringer Ingelheim

Novel HIV integrase inhibitors in early development at BMS

Merck researchers develop new macrocyclic BACE inhibitors

New porphyrin derivatives and their use in cancer radiotherapy

New antitumor conjugates with improved half-life designed at Bracco

Cambridge Laboratories acquires U.K. rights to palonosetron

Sirna Therapeutics files IND to advance Sirna-027 into clinic

Mylan and King proceed with acquisition plans

Series B financing at MAP Pharmaceuticals to advance inhaled drug products

Vertex completes dosing in phase Ia study of VX-950 for HCV

Sunesis and Biogen Idec collaborate on small molecule oncology products

VaxGen cleared to begin clinical testing of smallpox vaccine LC16m8

Taisho and Arena identify potent MCH receptor antagonist ATC-0065

Novel small molecule VLA-4 antagonist for asthma reported by Uriach

Serono highlights second quarter developments

Crucell updates PER.C6 development

Schering-Plough reviews recent significant developments

First phase II Oxycyte protocol submitted

Good patient satisfaction achieved with Respimat SMI in the management of COPD

Clinical evidence suggests that TH-9507 improves functional performance of COPD patients

Treatment commences in West Nile study of Alferon N

Therapeutic benefits of the PPAR agonist muraglitazar in diabetes

Takara Bio and CAMS to codevelop cancer immunotherapies in China

ZymoGenetics and Serono establish broad alliance

Crucell signs PER.C6 license agreement with MorphoSys

Vioxx approved for once-daily treatment of juvenile rheumatoid arthritis

MB-06322 demonstrates activity in preclinical models of diabetes

Activity of BLX-1002 assessed in vitro, in vivo

Novel, selective chemokine CXCR2 receptor antagonist SB-656933 inhibits neutrophil CD11b expression

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...